NasdaqGS:ROIVBiotechs
How Investors May Respond To Roivant Sciences (ROIV) Accelerating Brepocitinib Timelines And Patent Litigation
Earlier in December 2025, Roivant Sciences reported faster-than-expected progress across several late-stage drug programs, including updated timelines for brepocitinib in dermatomyositis and non-infectious uveitis, continued advancement of mosliciguat in pulmonary hypertension associated with interstitial lung disease, and ongoing global lipid nanoparticle patent litigation involving Moderna, Pfizer, and BioNTech.
These pipeline accelerations, coupled with active portfolio management through...